Targeting the ubiquitin pathway in lymphoid malignancies
Ubiquitination and related cellular processes control a variety of aspects in human cell biology, and defects in these processes contribute to multiple illnesses. In recent decades, our knowledge about the pathological role of ubiquitination in lymphoid cancers and therapeutic strategies to target t...
| Main Authors: | , , |
|---|---|
| Format: | Journal Article |
| Published: |
Elsevier
2024
|
| Online Access: | http://hdl.handle.net/20.500.11937/95222 |
| _version_ | 1848765987599417344 |
|---|---|
| author | Li, Boheng Eichhorn, Pieter Chng, Wee-Joo |
| author_facet | Li, Boheng Eichhorn, Pieter Chng, Wee-Joo |
| author_sort | Li, Boheng |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Ubiquitination and related cellular processes control a variety of aspects in human cell biology, and defects in these processes contribute to multiple illnesses. In recent decades, our knowledge about the pathological role of ubiquitination in lymphoid cancers and therapeutic strategies to target the modified ubiquitination system has evolved tremendously. Here we review the altered signalling mechanisms mediated by the aberrant expression of cancer-associated E2s/E3s and deubiquitinating enzymes (DUBs), which result in the hyperactivation of oncoproteins or the frequently allied downregulation of tumour suppressors. We discuss recent highlights pertaining to the several different therapeutic interventions which are currently being evaluated to effectively block abnormal ubiquitin-proteasome pathway and the use of heterobifunctional molecules which recruit the ubiquitination system to degrade or stabilize non-cognate substrates. This review aids in comprehension of ubiquitination aberrance in lymphoid cancers and current targeting strategies and elicits further investigations to deeply understand the link between cellular ubiquitination and lymphoid pathogenesis as well as to ameliorate corresponding treatment interventions. |
| first_indexed | 2025-11-14T11:43:59Z |
| format | Journal Article |
| id | curtin-20.500.11937-95222 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T11:43:59Z |
| publishDate | 2024 |
| publisher | Elsevier |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-952222024-07-03T03:27:54Z Targeting the ubiquitin pathway in lymphoid malignancies Li, Boheng Eichhorn, Pieter Chng, Wee-Joo Ubiquitination and related cellular processes control a variety of aspects in human cell biology, and defects in these processes contribute to multiple illnesses. In recent decades, our knowledge about the pathological role of ubiquitination in lymphoid cancers and therapeutic strategies to target the modified ubiquitination system has evolved tremendously. Here we review the altered signalling mechanisms mediated by the aberrant expression of cancer-associated E2s/E3s and deubiquitinating enzymes (DUBs), which result in the hyperactivation of oncoproteins or the frequently allied downregulation of tumour suppressors. We discuss recent highlights pertaining to the several different therapeutic interventions which are currently being evaluated to effectively block abnormal ubiquitin-proteasome pathway and the use of heterobifunctional molecules which recruit the ubiquitination system to degrade or stabilize non-cognate substrates. This review aids in comprehension of ubiquitination aberrance in lymphoid cancers and current targeting strategies and elicits further investigations to deeply understand the link between cellular ubiquitination and lymphoid pathogenesis as well as to ameliorate corresponding treatment interventions. 2024 Journal Article http://hdl.handle.net/20.500.11937/95222 10.1016/j.canlet.2024.216978. http://creativecommons.org/licenses/by/4.0/ Elsevier fulltext |
| spellingShingle | Li, Boheng Eichhorn, Pieter Chng, Wee-Joo Targeting the ubiquitin pathway in lymphoid malignancies |
| title | Targeting the ubiquitin pathway in lymphoid malignancies |
| title_full | Targeting the ubiquitin pathway in lymphoid malignancies |
| title_fullStr | Targeting the ubiquitin pathway in lymphoid malignancies |
| title_full_unstemmed | Targeting the ubiquitin pathway in lymphoid malignancies |
| title_short | Targeting the ubiquitin pathway in lymphoid malignancies |
| title_sort | targeting the ubiquitin pathway in lymphoid malignancies |
| url | http://hdl.handle.net/20.500.11937/95222 |